ACRUX LIMITED — Capital/Financing Update 2014

Jul 24, 2014

25 JULY 2014

ACRUX (ACR) – ASX ANNOUNCEMENT

AXIRON NET SALES, QUARTER TO 30 JUNE 2014

Acrux (ASX: ACR) today confirmed that Eli Lilly reported global Axiron net sales of US$47.1 million in its financial results for the quarter ending 30 June 2014, up from US$39.5 million for the previous quarter to 31 March 2014.

Axiron net sales for Acrux’s financial year ended 30 June 2014 are shown in the following table:

Q3 2013	Q4 2013	Q1 2014	Q2 2014	Total FY 2014
US$40.6m	US$53.9m	US$39.5m	US$47.1m	US$181.1m

For the fiscal year ending 30 June 2014, Acrux earned royalties from Axiron of US$22.3 million, up from US$14 million in the previous year.

In addition to royalties, Acrux earned a milestone payment of US$25 million in March 2014 as the worldwide net sales of Axiron in the 2013 calendar year exceeded US$100 million.

Contact

Ross Dobinson, Executive Chairman: 03 9691 5920

About Acrux

• Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.

• The Acrux technology, used in marketed products including Axiron®, Evamist® and Recuvyra™, is based on a fast-drying, small volume, accurately dosed solution, containing penetration enhancers, that when applied topically, deposits drug through the skin for long acting delivery.

• Acrux has three products marketed by licensees in the USA, three products approved in Europe, and further products at earlier stages of development

==> picture [123 x 66] intentionally omitted <==

==> picture [360 x 66] intentionally omitted <==

==> picture [106 x 66] intentionally omitted <==